Octapharma announced today the results from the ProDERM study on the efficacy and safety of Octagam® 10% [Immune Globulin Intravenous (Human)], in adult dermatomyositis (DM) patients have been published in the New England Journal of Medicine (Aggarwal R et al. “Trial of Intravenous Immune Globulin in Dermatomyositis”)

Click here for more details

One comment on “ProDERM study results of Octagam® 10% treatment in patients with dermatomyositis published in the New England Journal of Medicine”

  1. 1
    Debra Hillard on February 3, 2023

    Dr. Aggarwal, I am very interested in this product as a victim of dermatomyositis. I would really like and need to contact you with many questions I have. Do you have another email I may contact you if you so allow, knowing here and now is not the time or place. Thank you for your consideration.

Leave a Reply

Your email address will not be published. Required fields are marked *